Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $38.6000 (2.96%) ($36.3700 - $38.6000) on Thu. Jul. 8, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.86% (three month average) | RSI | 55 | Latest Price | $38.6000(2.96%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.1% a day on average for past five trading days. | Weekly Trend | TGTX advances 1.8% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(68%) ARKG(63%) ARKK(59%) IWO(59%) IBB(58%) | Factors Impacting TGTX price | TGTX will decline at least -1.43% in a week (0% probabilities). VIXM(-46%) VXX(-38%) UUP(-19%) UNG(-3%) TLT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.43% (StdDev 2.86%) | Hourly BBV | 0.2 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $39.14(-1.38%) | 10 Day Moving Average | $39.01(-1.05%) | 20 Day Moving Average | $38.37(0.6%) | To recent high | -16.9% | To recent low | 19% | Market Cap | $4.889b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |